{'fraction_non_alphanumeric': 0.02987012987012987, 'fraction_numerical': 0.007792207792207792, 'mean_word_length': 5.2682926829268295, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prophylactic treatment for prevention of joint disease in hemophilia--cost versus benefit.

Patients with severe hemophilia number only around 400,000 worldwide, but their lifespan has increased because of improved treatment, and with that the prevalence of the disease is increasing. Despite the relatively small number of patients with severe hemophilia, the disease has an important socioeconomic effect because of its distinctive feature: a level of clotting factor (factor VIII or factor IX) so low that without replacement therapy, frequent hemorrhages occur, most often in the ankle, knee, and elbow joints. These joint hemorrhages culminate in a severe arthropathy, with signs of inflammation (as in rheumatoid arthritis) as well as degenerative damage (as . . .